CLGN
CollPlant Biotechnologies Ltd.
NasdaqCMUSDEQUITY
DELAYED
Last price
0.31
▲ 0.01 (4.90%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
0.30
Prev close
0.30
Day high
0.32
Day low
0.30
Volume
30.64K
Market cap
—
P/E (TTM)
—
52W range
0.27 – 3.18
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-5.45%
-4.1%
1M
0.00%
-3.7%
3M
-25.71%
-28.8%
6M
-49.35%
-60.4%
YTD
-77.71%
-90.0%
1Y
-84.14%
-104.1%
3Y
-94.99%
-169.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.37M | $515.00K | $10.96M | $299.00K | +360.4% |
| Operating revenue | $2.37M | $515.00K | $10.96M | $299.00K | +360.4% |
| Cost of revenue | $835.00K | $1.63M | $1.99M | $400.00K | -48.6% |
| Gross profit | $1.54M | -$1.11M | $8.97M | -$101.00K | +238.4% |
| Research & development | $8.19M | $10.52M | $10.48M | $10.26M | -22.1% |
| Selling, general & admin | $4.83M | $5.63M | $6.00M | $6.74M | -14.1% |
| Total operating expense | $13.02M | $16.14M | $16.48M | $17.00M | -19.3% |
| Operating income | -$11.48M | -$17.25M | -$7.51M | -$17.10M | +33.4% |
| Net interest income | $365.00K | $721.00K | $778.00K | $287.00K | -49.4% |
| Pre-tax income | -$11.49M | -$16.61M | -$7.02M | -$16.93M | +30.8% |
| Net income | -$11.49M | -$16.61M | -$7.02M | -$16.93M | +30.8% |
| Net income to common | -$11.49M | -$16.61M | -$7.02M | -$16.93M | +30.8% |
| Basic EPS | -0.94 | -1.45 | -0.62 | -1.53 | +35.2% |
| Diluted EPS | -0.94 | -1.45 | -0.62 | -1.53 | +35.2% |
| EBIT | -$11.48M | -$17.25M | -$7.51M | -$17.10M | +33.4% |
| EBITDA | -$10.57M | -$16.21M | -$6.41M | -$16.02M | +34.8% |
| Basic shares | 12.20M | 11.45M | 11.39M | 11.03M | +6.5% |
| Diluted shares | 12.20M | 11.45M | 11.39M | 11.03M | +6.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $5.59M | $11.91M | $26.67M | $29.65M | -53.1% |
| Cash & short-term investments | $5.59M | $11.91M | $26.67M | $29.65M | -53.1% |
| Accounts receivable | $1.00K | $150.00K | $0 | $9.00K | -99.3% |
| Inventory | $573.00K | $440.00K | $714.00K | $1.43M | +30.2% |
| Total current assets | $6.75M | $13.18M | $28.02M | $31.66M | -48.8% |
| Property, plant & equipment | $3.89M | $5.28M | $5.86M | $5.68M | -26.4% |
| Goodwill & intangibles | $73.00K | $131.00K | $188.00K | $245.00K | -44.3% |
| Total assets | $10.79M | $18.71M | $34.13M | $37.77M | -42.4% |
| Total current liabilities | $2.67M | $2.97M | $3.25M | $3.10M | -10.0% |
| Total debt | $2.85M | $3.08M | $3.16M | $2.91M | -7.6% |
| Total liabilities | $4.70M | $5.25M | $5.79M | $5.49M | -10.3% |
| Retained earnings | -$124.84M | -$113.35M | -$96.74M | -$89.72M | -10.1% |
| Shareholder equity | $6.08M | $13.46M | $28.34M | $32.28M | -54.8% |
| Working capital | $4.08M | $10.21M | $24.77M | $28.55M | -60.1% |
| Net tangible assets | $6.01M | $13.33M | $28.15M | $32.04M | -54.9% |
| Shares issued | 12.82M | 11.47M | 11.47M | 11.19M | +11.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$11.49M | -$16.61M | -$7.02M | -$16.93M | +30.8% |
| Depreciation & amortisation | $912.00K | $1.04M | $1.10M | $1.08M | -12.1% |
| Stock-based compensation | $999.00K | $1.72M | $1.94M | $2.17M | -41.9% |
| Change in working capital | $254.00K | -$372.00K | $848.00K | -$544.00K | +168.3% |
| Operating cash flow | -$9.42M | -$14.09M | -$2.76M | -$13.70M | +33.2% |
| Capital expenditure | -$28.00K | -$483.00K | -$954.00K | -$1.32M | +94.2% |
| Investing cash flow | -$27.00K | -$539.00K | -$1.16M | $28.92M | +95.0% |
| Financing cash flow | $3.10M | $9.00K | $1.11M | $1.87M | +34,366.7% |
| Free cash flow | -$9.45M | -$14.58M | -$3.72M | -$15.01M | +35.2% |
| End cash position | $5.59M | $11.91M | $26.67M | $29.86M | -53.1% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $73.00K | $60.00K | $77.00K | $179.00K | $2.06M | +21.7% |
| Operating revenue | $73.00K | $60.00K | $77.00K | $179.00K | $2.06M | +21.7% |
| Cost of revenue | $316.00K | $192.00K | $269.00K | $186.00K | $188.00K | +64.6% |
| Gross profit | -$243.00K | -$132.00K | -$192.00K | -$7.00K | $1.87M | -84.1% |
| Research & development | $1.68M | $1.98M | $2.09M | $2.01M | $2.10M | -15.3% |
| Selling, general & admin | $1.19M | $1.04M | $1.23M | $1.16M | $1.41M | +15.0% |
| Total operating expense | $2.87M | $3.02M | $3.31M | $3.17M | $3.52M | -4.8% |
| Operating income | -$3.12M | -$3.15M | -$3.51M | -$3.18M | -$1.65M | +1.1% |
| Net interest income | $18.00K | $314.00K | $24.00K | -$169.00K | $196.00K | -94.3% |
| Pre-tax income | -$3.10M | -$3.21M | -$3.48M | -$3.35M | -$1.45M | +3.4% |
| Net income | -$3.10M | -$3.21M | -$3.48M | -$3.35M | -$1.45M | +3.4% |
| Net income to common | -$3.10M | -$3.21M | -$3.48M | -$3.35M | -$1.45M | +3.4% |
| Basic EPS | -0.23 | — | -0.27 | -0.28 | -0.13 | — |
| Diluted EPS | -0.23 | — | -0.27 | -0.28 | -0.13 | — |
| EBIT | -$3.12M | -$3.15M | -$3.51M | -$3.18M | -$1.65M | +1.1% |
| EBITDA | -$2.90M | -$2.93M | -$3.28M | -$2.95M | -$1.40M | +1.0% |
| Basic shares | 13.75M | — | 12.72M | 11.84M | 11.45M | — |
| Diluted shares | 13.75M | — | 12.72M | 11.84M | 11.45M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.26M | $5.59M | $8.55M | $11.43M | $10.73M | -23.8% |
| Cash & short-term investments | $4.26M | $5.59M | $8.55M | $11.43M | $10.73M | -23.8% |
| Accounts receivable | $8.00K | $1.00K | $11.00K | $0 | $0 | +700.0% |
| Inventory | $679.00K | $573.00K | $540.00K | $553.00K | $673.00K | +18.5% |
| Total current assets | $5.54M | $6.75M | $9.62M | $12.62M | $12.09M | -17.9% |
| Property, plant & equipment | $3.51M | $3.89M | $4.25M | $4.58M | $4.88M | -9.8% |
| Goodwill & intangibles | $59.00K | $73.00K | $88.00K | $102.00K | $116.00K | -19.2% |
| Total assets | $9.18M | $10.79M | $14.09M | $17.44M | $17.21M | -14.9% |
| Total current liabilities | $2.44M | $2.67M | $2.63M | $2.74M | $2.70M | -8.6% |
| Total debt | $2.65M | $2.85M | $2.94M | $3.03M | $2.84M | -6.9% |
| Total liabilities | $4.30M | $4.70M | $4.78M | $4.93M | $4.81M | -8.7% |
| Retained earnings | -$127.94M | -$124.84M | -$121.63M | -$118.15M | -$114.80M | -2.5% |
| Shareholder equity | $4.89M | $6.08M | $9.30M | $12.51M | $12.40M | -19.7% |
| Working capital | $3.10M | $4.08M | $6.99M | $9.88M | $9.39M | -24.0% |
| Net tangible assets | $4.83M | $6.01M | $9.22M | $12.40M | $12.28M | -19.7% |
| Shares issued | 14.44M | 12.82M | 12.79M | 12.73M | 11.47M | +12.6% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$3.10M | -$3.21M | -$3.48M | -$3.35M | -$1.45M | +3.4% |
| Depreciation & amortisation | $210.00K | $216.00K | $223.00K | $229.00K | $244.00K | -2.8% |
| Stock-based compensation | $180.00K | -$18.00K | $282.00K | $353.00K | $382.00K | +1,100.0% |
| Change in working capital | -$328.00K | $88.00K | $104.00K | $406.00K | -$344.00K | -472.7% |
| Operating cash flow | -$3.05M | -$2.94M | -$2.88M | -$2.44M | -$1.17M | -3.9% |
| Capital expenditure | -$6.00K | -$15.00K | -$1.00K | -$3.00K | -$9.00K | +60.0% |
| Investing cash flow | -$6.00K | -$15.00K | -$1.00K | -$3.00K | -$8.00K | +60.0% |
| Financing cash flow | $1.72M | $0 | $0 | $3.10M | $0 | — |
| Free cash flow | -$3.06M | -$2.95M | -$2.88M | -$2.44M | -$1.18M | -3.6% |
| End cash position | $4.26M | $5.59M | $8.55M | $11.43M | $10.73M | -23.8% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.32
-0.79% from price
SMA 20
0.31
-0.81% from price
SMA 50
0.33
-6.05% from price
SMA 100
0.37
-13.95% from price
SMA 200
0.87
-63.94% from price
EMA 12
0.32
-0.82% from price
EMA 26
0.32
-2.31% from price
EMA 50
0.34
-8.44% from price
RSI (14)
46.9
Neutral
MACD (12,26,9)
-0.00
Hist 0.00
ATR (14)
0.04
11.90% of price
Realised vol 30D
87.1%
Annualised
Bollinger upper
0.35
20, 2σ
Bollinger lower
0.28
20, 2σ
50 / 200 cross
Death
0.33 vs 0.87
Trend bias
Below 200
-63.94%
Risk profile
Beta vs SPY
1.32
More volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
87.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-91.3%
Peak to trough
Max drawdown 5Y
-98.8%
Peak to trough
ATR 14
0.04
11.90% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
CollPlant Biotechnologies Files Prospectus for Resale of 31 Million Shares
MT Newswires · 44d ago
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT
PR Newswire · 54d ago
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
PR Newswire · 86d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.